Source comparison
Side Effect Comparison
Both versions share common GH-related side effects because they act on the same receptor. The differences are in severity and pattern. Water retention Moderate to significant (constant GH) Mild (pulsatile, resolves between doses) Injection site reaction Mild r
This comparison does not assign a generated winner or score.
- Both versions share common GH-related side effects because they act on the same receptor. The differences are in severity and pattern.
- Water retention
- Moderate to significant (constant GH)
- Mild (pulsatile, resolves between doses)
- Injection site reaction
- Mild redness, occasional nodule
- Mild redness, less common
- Flushing/warmth
- Common, lasts hours
- Common, resolves in minutes
- Numbness/tingling (hands)
- More common (sustained IGF-1)
- Less common (transient IGF-1)
- Headaches
- Moderate in first 1-2 weeks
- Mild in first week
- Increased hunger
- Mild
- Moderate (especially stacked with GHRP)
- Vivid dreams
- Reported
- Frequently reported (pre-bed dosing)
- Insulin resistance risk
- Higher (sustained GH elevation)
- Lower (pulsatile, allows insulin reset)
- Joint stiffness
- More common
- Less common
- The DAC version's sustained GH elevation is responsible for its heavier side effect profile. Water retention is the most frequently cited complaint: users report 2-5 lbs of water weight gain in the first 2-3 weeks. This typically stabilizes but does not fully resolve while on protocol. The no-DAC version produces transient water retention that clears between doses.
- The insulin sensitivity difference deserves attention. Sustained GH elevation opposes insulin action continuously. Pulsatile GH allows insulin sensitivity to recover between pulses. For anyone with prediabetes, metabolic syndrome, or a family history of type 2 diabetes, the no-DAC version carries lower metabolic risk. Monitor fasting glucose and HbA1c every 6-8 weeks regardless of which version you choose.
- Both versions share the same contraindications: active cancer (GH and IGF-1 promote cell growth), pregnancy, pituitary disorders, and diabetic retinopathy. See the peptide safety guide for comprehensive contraindication information.